Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva, Alessandra Maciel Almeida, Francisco De Assis Acurcio & Juliana Alvares-Teodoro. (2021) Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 1011-1016.
Read now
Read now
Benjamin Chastek, Laura K. Becker, Chieh-I Chen, Puneet Mahajan & Jeffrey R. Curtis. (2017) Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. Journal of Medical Economics 20:5, pages 464-473.
Read now
Read now
Machaon MK Bonafede, Jeffrey R Curtis, Donna McMorrow, Puneet Mahajan & Chieh-I Chen. (2016) Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. ClinicoEconomics and Outcomes Research 8, pages 707-715.
Read now
Read now
Articles from other publishers (13)
Yinan Huang, Sandeep K. Agarwal, Hua Chen, Satabdi Chatterjee, Michael L. Johnson & Rajender R. Aparasu. (2023) Real-World Comparative Effectiveness of Methotrexate-Based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clinical Therapeutics.
Crossref
Crossref
Hawraa Kadhim Abbas, Dheyaa Jabbar Kadhim, Faiq Isho Gorial & Laith G. Shareef. (2022) Assessment of medication-related burden among a sample of Iraqi patients with systemic lupus erythematosus and its relationship with disease activity: a cross-sectional study. F1000Research 11, pages 970.
Crossref
Crossref
Hawraa Kadhim Abbas, Dheyaa Jabbar Kadhim, Faiq Isho Gorial & Laith G. Shareef. (2022) Assessment of medication-related burden among a sample of Iraqi patients with systemic lupus erythematosus and its relationship with disease activity: a cross-sectional study. F1000Research 11, pages 970.
Crossref
Crossref
Aliza R. Karpes Matusevich, Zhigang Duan, Hui Zhao, Lincy S. Lal, Wenyaw Chan, María E. Suarez‐Almazor, Sharon H. Giordano, J. Michael Swint & Maria A. Lopez‐Olivo. (2021) Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies. Arthritis Care & Research 73:10, pages 1461-1469.
Crossref
Crossref
Marina Amaral de Ávila Machado, Cristiano Soares de Moura, Steve Ferreira Guerra, Jeffrey R. Curtis, Michal Abrahamowicz & Sasha Bernatsky. (2018) Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Research & Therapy 20:1.
Crossref
Crossref
Ryan A. Popp, Karen Rascati, Matthew Davis & Ujas Patel. (2018) Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:2, pages 172-180.
Crossref
Crossref
Michael Grabner, Natalie N. Boytsov, Qing Huang, Xiang Zhang, Tingjian Yan & Jeffrey R. Curtis. (2017) Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. Arthritis Research & Therapy 19:1.
Crossref
Crossref
Anagha Nadkarni, Donna McMorrow, Chad Patel, Robert Fowler & David Smith. (2017) Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents. Journal of Comparative Effectiveness Research 6:8, pages 671-682.
Crossref
Crossref
Hendra Goh, Yu Heng Kwan, Yi Seah, Lian Leng Low, Warren Fong & Julian Thumboo. (2017) A systematic review of the barriers affecting medication adherence in patients with rheumatic diseases. Rheumatology International 37:10, pages 1619-1628.
Crossref
Crossref
Gundula Krack, Henning Zeidler & Jan Zeidler. (2016) Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods. Drugs - Real World Outcomes 3:3, pages 265-278.
Crossref
Crossref
Jeffrey A. Sparks, Alexis A. Krumme, William H. Shrank, Olga S. Matlin, Gregory Brill, Edmund J. Pezalla, Niteesh K. Choudhry & Daniel H. Solomon. (2016) Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014. Arthritis & Rheumatology 68:7, pages 1588-1595.
Crossref
Crossref
Marie Hudson, Koray Tascilar & Samy Suissa. (2016) Comparative effectiveness research with administrative health data in rheumatoid arthritis. Nature Reviews Rheumatology 12:6, pages 358-366.
Crossref
Crossref
Tao Gu, Neel Shah, Gaurav Deshpande, Derek H. Tang, Debra F. Eisenberg & David J. Harrison. (2015) Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study. Journal of Health Economics and Outcomes Research 3:2, pages 122-131.
Crossref
Crossref